A Phase II Study of Vandetanib in Patients With Non-small Cell Lung Cancer Harboring RET Rearrangement

Trial Profile

A Phase II Study of Vandetanib in Patients With Non-small Cell Lung Cancer Harboring RET Rearrangement

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Nov 2016

At a glance

  • Drugs Vandetanib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 01 Nov 2016 Status changed from recruiting to completed, according to results published in the Annals of Oncology.
    • 01 Nov 2016 Results published in the Annals of Oncology
    • 07 Jun 2016 Interim results (n=18) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top